Salesforce set for in-line quarter as investors watch AI traction

Jefferies' 20-partner survey indicates Salesforce's F3Q should come in broadly in line with consensus—partners were 70% at or above plan and expect growth to accelerate to ~10% in 2026 from 8% in 2025. Analysts see limited near-term upside (consensus: ~10% growth in remaining performance obligations and ~9% revenue growth) while investor focus centers on early monetization of Agentforce AI (roughly $440m, ~1% of revenue) and the pending Informatica deal, which is expected to add 3–4 percentage points to growth in fiscal 2027; Jefferies maintains a Buy and $375 target as shares trade ~31% YTD down and ~45% below peers on 2026 FCF multiples.

Analysis

Market structure: Salesforce (CRM) is a tactical beneficiary of steady enterprise SaaS spend — Jefferies’ partner survey shows 70% at/above plan and 55% seat growth — which supports baseline ARR stability while AI monetization is nascent ($440m, ~1% of revenue). The Informatica (INFA) deal, expected to add ~3–4ppt to growth in FY27, materially changes supply of data-management capabilities and should improve cross-sell economics, while the stock trades 31% YTD down and ~45% FCF multiple discount to peers, implying a re-rating option if execution meets targets.

Risk assessment: Tail risks include AI regulation, failed INFA integration, or rapid seat compression if per-user AI pricing displaces seats; these could knock 5–15% off revenue growth in adverse scenarios. Near-term (days-weeks) risk is muted given an in-line quarter; short-term (3–6 months) hinge on analyst day and FY26 guidance; long-term (FY27+) depends on Agentforce scale — meaningful margin/FCF improvement likely only if Agentforce reaches >3–5% of revenue (~$2.2B) and INFA synergies are realized.

Trade implications: Tactical long exposure to CRM is justified but size and structure must reflect timing risk — prefer 2–3% equity exposure paired with options: buy 9–12 month call spreads to capture re-rating tied to analyst-day guidance, cap cost and skew upside. Relative-value: long CRM vs short a higher-multiple AI darlings (e.g., long CRM / short MSFT neutralizes market beta) to capture 45% FCF-discount convergence; rotate into large-cap application software at expense of high-multiple early-stage AI plays.

Contrarian angle: Consensus underweights the inorganic boost from INFA + a multi-year Agentforce uptake curve — if paying Agentforce customers double over 12 months or Agentforce becomes 3%+ revenue by FY27 the market has likely over-penalized CRM. Conversely, the market may be underpricing integration risk and margin drag through FY26; watch paying-customer cadence and remaining-performance-obligations growth (>10% would be a positive shock). Historical parallel: earlier SaaS platform add-ons re-rated once 2–3 years of cross-sell proved sustainable; the same path is possible here but not guaranteed.

Key Decisions for Investors

• Establish a 2–3% long position in CRM ahead of the analyst day and FY26 guidance release; use size to limit drawdown and set tactical stop-loss at 18–20% below entry. Timeframe: add within 0–30 days pre/post analyst day.
• Buy a 9–12 month CRM call spread (debit) to capture upside on AI/INFA execution — target strikes ~30%/60% OTM relative to current price to limit premium and target 2x+ payoff if Agentforce >3% revenue by FY27. Exit: roll or unwind if Analyst Day fails to add clear paying-customer metrics within 90 days.
• Implement a pair trade: long CRM (2%) vs short MSFT (2%) to neutralize beta and isolate CRM-specific re-rating; rebalance after FY26 guidance or if spread narrows by 50% from current FCF-multiple differential (target convergence over 12–18 months).
• If CRM reports Agentforce paying-customer growth >50% YoY or guidance raises FY27 organic growth by >200bp, increase CRM exposure to 5% portfolio weight. Conversely, reduce to half if INFA integration guidance implies >200bp FY26 drag or paying-customer cadence misses by >30%.